Resumo

ROSANOVA, María T et al. Ánidulafungin in children: Experience in a tertiary care children's hospital in Argentina. Arch. argent. pediatr. [online]. 2017, vol.115, n.4, pp.374-376. ISSN 0325-0075.  http://dx.doi.org/10.5546/aap.2017.374.

The experience using anidulafungin for the treatment of invasive fungal infections in pediatrics is limited. In this article, we describe our experience in 55 children. Anidulafungin was administered intravenously at a loading dose of 3 mg/kg once daily, followed by 1.5 mg/kg every 24 hours over a mean period of 14 days (range: 7-22 days). Patients' median age was 114 months old (interquartile range: 32-168 months old). All patients had underlying diseases. Among patients with bone marrow transplant, the difference in white blood cell count, transaminase levels, and renal function at baseline and at the end of anidulafungin administration was not significant. No adverse events were reported and no patient died from an anidulafungin-related cause. Anidulafungin may be considered an alternative for the prophylaxis or treatment of invasive fungal infections in pediatrics but methodologically robust studies are needed to confirm this.

Palavras-chave : Anidulafungin; Children; Invasive fungal infections.

        · resumo em Espanhol     · texto em Espanhol     · Inglês ( pdf ) | Espanhol ( pdf )